(Q37168014)

18 August 2017

1 reference

title

Treating patients with lupus with B-cell depletion (English)

1 reference

18 August 2017

1

D A Isenberg

1 reference

18 August 2017

publication date

1 May 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

17

1 reference

18 August 2017

issue

5

1 reference

18 August 2017

page(s)

400-404

1 reference

BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090024

An open study of B lymphocyte depletion in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090024

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090024

B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090024

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090024

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090024

Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090024

CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090024

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090024

BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090024

T cell costimulation by the TNF ligand BAFF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090024

BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090024

B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090024

Correlation of the expression levels of BLyS and its receptors mRNA in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090024

Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0961203308090024

21 January 2018

Identifiers

DOI

10.1177/0961203308090024

1 reference

18 August 2017

1 reference